Left Atrial Appendage Occlusion Complicated by Appendage Perforation Rescued by Device Deployment

Anna Sarcon, MS, MD1, Dipayon Roy, MD1, David Laughrun, MD1, Mary Huntsinger, ACNP1, Jacqueline Schwartz, MD1, Jina Sohn, MD1, and Rahul N. Doshi, MD, FHRSM1

Abstract
The Watchman device is a transcatheter left atrial appendage (LAA) occluding device used in patients with nonvalvular atrial fibrillation (NVAF) and a high CHADS2-VASc score who are poor long-term anticoagulation candidates. Pericardial effusion related to device deployment and perforation can be a life-threatening complication. While not common in hands of experienced operators, management may require surgical intervention. Here we present a rare case of LAA perforation, which was corrected by successful repositioning of the device foregoing the need for surgical management.

Keywords
left atrial appendage occlusion, Watchman, pericardial effusion

Background
The Watchman device is the first US Food and Drug Administration–approved transcatheter left atrial appendage (LAA) occluding device used in patients with nonvalvular atrial fibrillation (NVAF) and a high CHADS2-VASc score who are poor long-term anticoagulation candidates. In NVAF, LAA is the most common source of cardiac thromboembolism, and its occlusion can reduce the risk of thromboembolic events in a selected patient population. One of the procedural complications of the Watchman procedure is perforation related to device deployment. In the PROTECT AF trial, device-related complications were noted to be 8.7%. The specific rate of pericardial effusion was 4.5%, with 3.3% requiring pericardiocentesis or surgical intervention. More recently, data from the EWOLUTION registry note the rate of pericardial effusion to be 4.1%, with 1.4% of patients requiring surgical management of procedure-related pericardial effusion, with no patients dying as a result of these effusions or subsequent management. Despite the declining rate of complications with increasing implanters experience and device approval, a small risk of pericardial effusion requiring surgical intervention remains. Here we present a rare case of LAA perforation, which was corrected by successful repositioning of the device foregoing the need for surgical management.

Case Presentation
A 73-year-old man with history of NVAF, hypertension, bradycardia requiring pacemaker implantation, and history of upper gastrointestinal bleed while on anticoagulation was deemed a good candidate for LAA occlusion device implantation. His CHA2DS2-VASc score was 3, for diastolic heart failure, age, and history of hypertension, and HAS-BLED score was calculated to be 4, putting him at elevated risk for another serious bleed while on therapeutic anticoagulation. The procedure was performed under general anesthesia, and transseptal access was performed with transesophageal echocardiography (TEE) and fluoroscopy guidance. His maximum LAA width measured by echocardiography was 21 mm with maximum depth, 27 mm, measured to the anterior lobe. A 27-mm Watchman device was selected and prepped in the usual fashion and delivered via a dual curve sheath. The activated clotting time during deployment was 213 seconds. As the device was being delivered through the sheath at the area of greatest curvature, the sheath whipped anteriorly before the device exited. Contrast injection during fluoroscopy revealed pericardial staining. Given a presumptive diagnosis of LAA perforation, the device was deployed with sheath remaining in the same distal position given the concern for losing LAA access. After deployment, angiography revealed successful occlusion. The patient was discharged without complications and continues to be well on anticoagulation therapy.
the sheath confirmed LAA laceration, with TEE visualization of the device in the transverse sinus (Figure 1). Given increasing hypotension, 2 pericardial drains were placed with acute evacuation of approximately 1 L of blood. The patient was immediately transfused with packed red blood cells, and anticoagulation was reversed with protamine with the sheath remaining in the atrium. The patient was hemodynamically stabilized but required continuous pericardial drainage despite reversal of anticoagulation. Given the presence of an intact proximal portion of the LAA, the decision was made to deploy the device in the LAA to provide an impediment to blood loss. Following device deployment guided primarily by TEE visualization of the delivery sheath, there was an almost immediate cessation of fluid accumulation in the pericardial space. The patient remained hemodynamically stable and transferred to intensive care unit for further monitoring. The patient was kept sedated and intubated to assure stabilization. On postoperative day (POD) 2, a TEE revealed trace pericardial effusion with adequate device position and no peri-device leak (Figure 2). The patient was subsequently extubated. A repeat echocardiogram showed only trivial pericardial effusion on POD 4. The patient was maintained on dual antiplatelet therapy (DAPT) and colchicine, and he was discharged home on POD 5. Computed tomography of the chest, 1-month postimplantation, showed adequate positioning of the device without any evidence of extravasation or device-related thrombus (Figure 3).

**Discussion**

While transcatheter closure of LAA is less invasive than surgical exclusion of the LAA from the systemic circulation, it remains a complex procedure and can be associated with serious complications. These complications are mainly attributed to techniques necessary in deploying the LAA closure device, including transseptal puncture and manipulation of stiff wires and guide catheters in the left atrium/LAA. The Watchman device has been shown to have equivalent follow-up results in randomized controlled trials compared with traditional vitamin K antagonist therapy with a low overall complication rate, as well as a potential for long-term mortality benefits secondary to a decreased risk of bleeding.

One of the most serious complications of LAA occlusion is pericardial effusion resulting in tamponade. Data from the PROTECT-AF trial showed rate of pericardial effusion within 7 days of Watchman implantation to be 4.5%, of which 3.3% of patients required pericardiocentesis or surgical intervention. Other complications include stroke secondary to thrombus or air embolism, device migration or dislodgement, and vascular complications. Complication rates related to the procedure appear to be decreasing despite an increased number of novel implanters since device commercialization.

In the PROTECT-AF study, the recommended anticoagulation regimen post device deployment was 45 days of warfarin.
followed by DAPT until 6 months postprocedure. In this patient, we chose to keep the patient only on DAPT therapy. The EWOLUTION trial has recently been presented and demonstrates low risk of device-related thrombosis with only DAPT therapy. This approach needs to be validated in prospective trials whether equivalent to vitamin K antagonists. The patient presented here has not shown any evidence of device-related thrombosis on computed tomography scan 1 month postprocedure and has no evidence of recurrent bleeding.

To our knowledge, this is the first case demonstrating the use of the Watchman device to stabilize a patient with a life-threatening perforation of the LAA. The device consists of a Nitinol basket with a semipermeable membrane made of polyethylene terephthalate (Dacron). Thus, the 160-µm pore filter should easily allow blood flow through the membrane. We speculate that the activated clotting cascade initiated by the injury was facilitated by the scaffold provided by the membrane that could enable platelet adhesion and aggregation and lead to immediate cessation of bleeding, similar to hemostatic devices used for surgical bleeding. In addition, the fixation mechanism of the device allowed for stable deployment in the proximal portion of the LAA ostium.

**Conclusion**

Device- and procedure-related complications can occur with LAA occlusion and may have life-threatening complications such as cardiac tamponade. We describe a case of Watchman device deployment in which the device complication was managed in part by the device itself.

**Acknowledgment**

We thank Drs Jerold Shinbane and Jina Sohn, University of South California, Division of Cardiology, for providing the computed tomography and transesophageal images.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

---

**Figure 2.** Transesophageal echocardiography images with color Doppler 2 days after device placement shows Watchman deep in the left atrial appendage, without significant peri-device leak. Fluid is no longer apparent in the transverse sinus.

**Figure 3.** Computed tomography chest 1-month postprocedure showing adequate device positioning (blue arrow) with a small residual pericardial effusion (red arrow).
Ethics Approval
Our institution does not require ethical approval for reporting individual cases.

Informed Consent
Informed consent for patient information to be published in this article was not obtained because the information is completely anonymous and no identifying factors are linked to the case.

References
1. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-759.
2. Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J. 2006;151:956-961.
3. Reddy VY, Gibson DN, Kar S, et al. Post-approval US experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2017;69:253-261.
4. Boersma LVA, Schmidt B, Betts TR, et al; EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016;37:2465-2474.
5. Möbius-Winkler S, Majunke N, Sandri M, et al. Percutaneous left atrial appendage closure: technical aspects and prevention of periprocedural complications with the Watchman device. World J Cardiol. 2015;7:65-75.
6. Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374:534-542.
7. Reddy VY, Doshi SK, Kar S, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964-2975.
8. Bayard YL, Omran H, Neuzil P, et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention. 2010;6:220-226.